Shares of TG Therapeutics, Inc. (TGTX) have traded between $4.58 – 16.22. The next earnings date is set for Feb 25, 2020. Let’s see how its prospects are shaping up.

What does TG Therapeutics, Inc.(TGTX) do?

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

TGTX Insider Trading Insight

On 2019-07-01, Power Sean A CFO, Secretary, Treasurer sold 17,654 shares of TGTX. That represents a value of $383,338. Not to be outdone, on 2019-06-26, Weiss Michael S P – Purchase bought50,000 shares of TGTX. These insiders are clearly in the know because they work closely with the company.

ACA Intraday Trading

ACA is due to report earnings on Feb 26, 2020. In the last year the price has ranged from 28.35 – 47.85. Recently, Valueact Holdings, L.P. sold 1,395,000 shares of ACA. He is a $54,045,000 shareholder in ACA.

Looking for stocks similar to TGTX and ACA?

Here are some stocks to consider: